Cedric Portugues

Pierre-la-treiche, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Journal: Blood advances

Published: August 11, 2025

Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Journal: Blood advances

Published: August 11, 2025

Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off Approach.

Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off Approach.

Journal: Hematological oncology

Published: January 13, 2025

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Journal: Blood

Published: November 18, 2024

Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA.

Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA.

Journal: EClinicalMedicine

Published: October 25, 2024

Precautions to Consider in the Analysis of Prognostic and Predictive Indices.

Precautions to Consider in the Analysis of Prognostic and Predictive Indices.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 15, 2024

Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Journal: Nature medicine

Published: May 14, 2024

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Journal: Nature medicine

Published: October 09, 2023

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 15, 2023

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Journal: Nature medicine

Published: May 25, 2023

Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment.

Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment.

Journal: British journal of haematology

Published: November 07, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026